KUALA LUMPUR, Jan 11 (Bernama) -- Medidata, a Dassault Systèmes company and provider of clinical trial solutions to the life sciences industry, has again been recognised as a Leader in Everest Group’s recently published “Decentralized Clinical Trials Platforms PEAK Matrix Assessment 2023”.
According to a statement, Medidata was the only provider to receive a “Star Performer” designation for the second consecutive year, reflecting its continued innovation and leadership.
Medidata Patient Cloud chief executive officer, Anthony Costello said Medidata’s unified platform harnessed decentralised clinical trial (DCT) technology to optimise patient, site, and sponsor experiences, delivering more inclusive studies.
“We are honoured to be recognised as a Leader by Everest Group in DCT platform providers, demonstrating our extensive experience and leadership in a rapidly evolving industry,” he said.
The report evaluated the vision, capabilities, and market impact of 22 DCT platform providers based on relevant customer case studies, revenue, key offerings, and their latest progress.
In this year’s assessment, Medidata distinguished itself through substantial investments in next-generation and patient-centric DCT technologies within Medidata artificial intelligence (AI) and Medidata Patient Cloud, such as the Medidata Diversity Program, the myMedidata application, and Medidata Rave Companion.
As a Leader, Medidata was also recognised for its domain expertise and user experience for patients and sites, as well as its global capabilities to orchestrate DCTs.
Medidata’s platform has powered nearly 1,700 DCTs and over 1.1 million patients across disease areas, countries, languages, and clinical trial phases. With this technology, Medidata supports patient participation in the right trial at the right time, from anywhere and with easier, faster, and better results.
-- BERNAMA
No comments:
Post a Comment